396 related articles for article (PubMed ID: 26383518)
1. A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?
Mirzaei A; Tavoosidana G; Rad AA; Rezaei F; Tavakoli-Yaraki M; Kadijani AA; Khalili E; Madjd Z
Tumour Biol; 2016 Feb; 37(2):2405-14. PubMed ID: 26383518
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.
Mirzaei A; Tavoosidana G; Modarressi MH; Rad AA; Fazeli MS; Shirkoohi R; Tavakoli-Yaraki M; Madjd Z
Tumour Biol; 2015 Jun; 36(6):4801-10. PubMed ID: 25631749
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer.
Gzil A; Zarębska I; Jaworski D; Antosik P; Durślewicz J; Maciejewska J; Domanowska E; Skoczylas-Makowska N; Ahmadi N; Grzanka D; Szylberg Ł
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2547-2557. PubMed ID: 32671503
[TBL] [Abstract][Full Text] [Related]
4. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
Kang XL; He LR; Chen YL; Wang SB
World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methods.
Mirzaei A; Madjd Z; Kadijani AA; Tavakoli-Yaraki M; Modarresi MH; Verdi J; Akbari A; Tavoosidana G
Cancer Biomark; 2016 Sep; 17(3):301-311. PubMed ID: 27802206
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
7. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer.
Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D
Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103
[TBL] [Abstract][Full Text] [Related]
8. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas.
Kalantari E; Asadi Lari MH; Roudi R; Korourian A; Madjd Z
Cancer Biomark; 2017 Dec; 20(4):563-573. PubMed ID: 28946555
[TBL] [Abstract][Full Text] [Related]
9. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
10. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
Gao T; Wang M; Xu L; Wen T; Liu J; An G
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
[TBL] [Abstract][Full Text] [Related]
11. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.
Razi S; Sadeghi A; Asadi-Lari Z; Tam KJ; Kalantari E; Madjd Z
Clin Exp Med; 2021 Feb; 21(1):139-147. PubMed ID: 32965580
[TBL] [Abstract][Full Text] [Related]
12. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance.
He S; Zhou H; Zhu X; Hu S; Fei M; Wan D; Gu W; Yang X; Shi D; Zhou J; Zhou J; Zhu Z; Wang L; Li D; Zhang Y
Biomed Pharmacother; 2014 Jun; 68(5):507-13. PubMed ID: 24751002
[TBL] [Abstract][Full Text] [Related]
13. The Expression Analysis of Intestinal Cancer Stem Cell Marker Lgr5 in Colorectal Cancer Patients and the Correlation with Histopathological Markers.
Salehzadeh S; Hasanzad M; Kadijani AA; Akbari A
J Gastrointest Cancer; 2020 Jun; 51(2):591-599. PubMed ID: 31422541
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.
Shafiei S; Kalantari E; Saeednejad Zanjani L; Abolhasani M; Asadi Lari MH; Madjd Z
Exp Mol Pathol; 2019 Jun; 108():164-172. PubMed ID: 31028726
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer.
Valladares-Ayerbes M; Blanco-Calvo M; Reboredo M; Lorenzo-Patiño MJ; Iglesias-Díaz P; Haz M; Díaz-Prado S; Medina V; Santamarina I; Pértega S; Figueroa A; Antón-Aparicio LM
Int J Mol Sci; 2012; 13(4):4367-4387. PubMed ID: 22605983
[TBL] [Abstract][Full Text] [Related]
17. Lgr5 Methylation in Cancer Stem Cell Differentiation and Prognosis-Prediction in Colorectal Cancer.
Su S; Hong F; Liang Y; Zhou J; Liang Y; Chen K; Wang X; Wang Z; Wang Z; Chang C; Han W; Gong W; Qin H; Jiang B; Xiong H; Peng L
PLoS One; 2015; 10(11):e0143513. PubMed ID: 26599100
[TBL] [Abstract][Full Text] [Related]
18. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of doublecortin-like kinase 1 expression in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Harada Y; Kazama S; Morikawa T; Emoto S; Murono K; Kaneko M; Sasaki K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Hata K; Nozawa H; Ishihara S; Watanabe T
APMIS; 2018 Jun; 126(6):486-493. PubMed ID: 29924454
[TBL] [Abstract][Full Text] [Related]
20. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
